Apogee Therapeutics, Inc Common Stock

Apogee Therapeutics, Inc Common Stock

Yahoo Finance • 8 days ago

XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets?

The State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) provides broad exposure to the biotech industry, while the First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) offers a much more concentrated, equal-weighted alternative. Biote... Full story

Yahoo Finance • 8 days ago

Billionaire Ken Griffin Increased His Position in This Dividend King by 547%

Billionaire hedge fund manager Ken Griffin was in the news after he scooped up most of the public stock portfolio formerly held by Situational Awareness late last month. In what was otherwise a bad month for hedge funds, Griffin's Citadel... Full story

Yahoo Finance • 16 days ago

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

AbbVie (NYSE: ABBV) is aiming high with its $10.6 billion planned purchase of Apogee Therapeutics (NASDAQ: APGE). The deal, pending regulatory approvals, is expected to close in the third quarter. The move is designed to supplement the ph... Full story

Yahoo Finance • 17 days ago

High-flyer healthcare stocks: Ten names with strong momentum, weak valuations

[Heart Health Concept] Eoneren/E+ via Getty Images Wall Street investors are increasingly seeking refuge in high-performing equity plays as volatile healthcare markets continue to shift, forcing a critical evaluation of stock price veloci... Full story

Yahoo Finance • 18 days ago

iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?

Investors choosing between iShares Global Healthcare ETF (NYSEMKT:IXJ) and State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) must weigh the high-growth potential of specialized U.S. biotech against a more stable, dividend-paying global healt... Full story

Yahoo Finance • 19 days ago

AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed

In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of n... Full story

Yahoo Finance • 21 days ago

This Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now

Key Points AbbVie posted solid second-quarter financial results, led by its two most important products, Skyrizi and Rinvoq. The company's portfolio and pipeline should help maintain steady revenue and earnings over the medium term. AbbV... Full story

Yahoo Finance • 22 days ago

Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48%... Full story

Yahoo Finance • 22 days ago

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index down 0.7% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 23 days ago

Merck, Pfizer Lift Full-Year Sales Outlooks Following Second-Quarter Beats

Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both ph PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 26 days ago

AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition

AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 27 days ago

AbbVie shares fall on earnings miss and weak guidance

Investing.com -- AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings before the open on Friday, missing profit expectations, although revenue beat the consensus estimate. Adjusted earnings per share came in at $3.65, missing analyst... Full story

Yahoo Finance • 27 days ago

AbbVie Earnings Preview: Immunology portfolio remains in focus amid Humira decline

[AbbVie] hapabapa AbbVie (ABBV [https://seekingalpha.com/symbol/ABBV]) is projected to report a solid second-quarter print, with double-digit growth seen for both top and bottom lines. EPS is expected to go up 67% Y/Y to $3.61 [https://s... Full story

Yahoo Finance • last month

Why Wall Street Can't Get Enough of This Dividend King

AbbVie (NYSE: ABBV) was spun off from Abbott (NYSE: ABT) in 2013. That's an important fact to keep in mind when you look at AbbVie's Dividend King status. Technically, it hasn't increased its dividend annually for 50 years because it hasn'... Full story

Yahoo Finance • last month

Halper Sadeh LLC is Investigating Whether NEE, CRBG, RMAX, APGE are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm... Full story

Yahoo Finance • last month

What This Apogee Insider Move Might Mean After a 247% Stock Run

Michael Thomas Henderson, Chief Executive Officer of Apogee Therapeutics, Inc. (NASDAQ:APGE), reported a disposition of 95,046 shares of common stock on July 8, 2026 and July 10, 2026, according to a recent SEC Form 4 filing. Transaction... Full story

Yahoo Finance • 2 months ago

Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?

Key Points Invesco Pharmaceuticals ETF offers a higher dividend yield and lower five-year beta than State Street SPDR S&P Biotech ETF State Street SPDR S&P Biotech ETF holds 155 securities compared to 30 in Invesco Pharmaceuticals ETF Inv... Full story

Yahoo Finance • 2 months ago

This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?

Key Points AbbVie recently announced an acquisition that may help it remain a leader in immunology. Between AbbVie's strong lineup, deep pipeline, and dividend program, there are many reasons to buy the stock.10 stocks we like better than... Full story

Yahoo Finance • 2 months ago

AbbVie (ABBV) Wins Health Canada Approval for Boey

AbbVie Inc. (NYSE:ABBV) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 23, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced that Health Canada approved Boey for the temporary improvement of m... Full story

Yahoo Finance • 2 months ago

AbbVie (ABBV) to Acquire Apogee Therapeutics

AbbVie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. AbbVie Inc. (NYSE:ABBV) and Apogee Therapeutics announced on June 22 their entry into a definitive agreement under which AbbVie Inc. (NYSE:ABBV) will acquire Apogee a... Full story